News ReleaseView printer-friendly version << Back
Pacira Pharmaceuticals, Inc. Reports Second Quarter EXPAREL® Revenue of $15.2 Million and Full Second Quarter 2013 Financial Results
Company Will Host Conference Call Today at
“The second quarter marks the commencement of the second year of launch,
and we are pleased with the strong sales growth and traction of
EXPAREL Commercialization: In the second quarter ended
June 30, 2013, EXPAREL sales totaled $15.2 million, up from $10.4 millionin the first quarter. Pacira continued its steady expansion, reporting 370 total new accounts in the second quarter, up from 246 new accounts in the previous quarter. Pacira also reported an average of 30 new customers per week for the second quarter of 2013. As of June 30, 2013, 1,435 total accounts ordered EXPAREL since launch, with 104 accounts ordering more than $100,000of EXPAREL each.
Data Continues to Shift the Pain Control Paradigm and Support the
Utility of EXPAREL Among Surgeons and Anesthesiologists
- Internal: During the second quarter, the Company announced a new study supporting the use of EXPAREL infiltrated into the transversus abdominis plane (or iTAP) for postsurgical analgesia in abdominal hernia repair. Additionally, Pacira recently published results from two studies in ileostomy reversal patients, the second and third in its prospective Phase 4 IMPROVE program.
External: Now that more surgeons and anesthesiologists have
experience with EXPAREL, they are beginning to present more of
their own findings. In May, a retrospective study led by
Jacob Hutchins, M.D., Director of Perioperative and Interventional Pain Service at the University of Minnesota’s Department of Anesthesiology, was presented on the use of EXPAREL in TAP infiltration for hand-assisted nephrectomies and colorectal procedures at the 2013 Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine(ASRA), showing low pain scores, high patient satisfaction, and no treatment-related adverse events. Data from a study conducted by the University of Texas Health Science Centerat the Bariatric Medical Institutecomparing the use of EXPAREL to an ON-Qpain ball in patients undergoing bariatric surgery were presented at the 2013 Annual Meeting of the Society of American Gastrointestinal and Endoscopic Surgeons(SAGES), which showed that patients treated with EXPAREL had improved pain scores and required less opioid.
EXPAREL net product sales for the quarter ended
June 30, 2013totaled $15.2 million, an increase of $12.9 millionfrom the reported $2.3 millionfor the corresponding period in 2012. This increase in net product sales was driven by a rise in the number of new accounts and an increase of orders within existing accounts, including hospital and ambulatory surgery centers, ordering EXPAREL. Total revenues for the quarter ended June 30, 2013were $17.1 millioncompared with $12.3 millionfor the quarter ended June 30, 2012. This increase was primarily driven by the $12.9 millionincrease in EXPAREL revenue for the second quarter partially offset by a $6.4 milliondecrease in collaborative licensing and development revenue due to the recognition of deferred revenue during 2012 associated with the termination of certain licensing agreements.
Total operating expenses for the quarter ended
June 30, 2013were $29.2 millioncompared with $19.0 millionfor the quarter ended June 30, 2012, an increase of $10.2 million. Cost of revenues increased $3.5 millionprimarily due to the cost of EXPAREL product sold. Research and development expenses increased $3.0 milliondue to clinical development costs for the ongoing pivotal trials of EXPAREL administered as a femoral nerve block for total knee arthroplasty surgery and as an intercostal nerve block for thoracotomy. Selling, general and administrative expenses increased $3.7 milliondue to greater commercialization efforts for EXPAREL.
Net loss for the quarter ended
June 30, 2013was $14.0 million, or $0.42per share (based on 33.1 million weighted average shares outstanding), compared to $8.3 million, or $0.27per share (based on 31.0 million weighted average shares outstanding) for the quarter ended June 30, 2012. As of June 30, 2013, the Company had 33.2 million shares of common stock outstanding.
Pacira ended the second quarter of 2013 with cash and cash
equivalents, restricted cash and short-term investments (“cash”) of
Today’s Conference Call and Webcast Reminder
The Pacira management team will host a conference call to discuss the
company’s financial results and recent and upcoming developments today,
A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), and providing the passcode 41170869. The replay of the call will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting in the same fashion as current local anesthetics. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing analgesia with reduced opioid requirements for up to 72 hours. Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy or hemorrhoidectomy procedures and additional studies are underway to further demonstrate the safety and efficacy in other procedures. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.
Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about our plans and
expectations regarding EXPAREL, and other statements containing the
words “believes,” “anticipates,” “plans,” “expects,” and similar
expressions, constitute forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including risks
relating to: the success of our sales and manufacturing efforts in
support of the commercialization of EXPAREL; the rate and degree of
market acceptance of EXPAREL; the size and growth of the potential
markets for EXPAREL and our ability to serve those markets; our plans to
expand the indications of EXPAREL to include nerve block, including
the timing and success of an sNDA; our plans to continue to manufacture
and provide support services for our commercial partners who have
licensed DepoCyt(e); our commercialization and marketing capabilities;
and other factors discussed in the “Risk Factors” of our most recent
Annual Report on Form 10-K for the fiscal year ended
|Pacira Pharmaceuticals, Inc.|
|Consolidated Statements of Operations|
|(in thousands, except share and per share amounts)|
|Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|Net product sales||$||16,278||$||4,981||$||27,113||$||5,427|
|Collaborative licensing and development revenue||243||6,600||486||13,090|
|Cost of revenues||10,214||6,685||21,605||13,180|
|Research and development||4,857||1,872||10,762||3,166|
|Selling, general and administrative||14,080||10,413||27,017||21,565|
|Total operating expenses||29,151||18,970||59,384||37,911|
|Loss from operations||(12,010||)||(6,626||)||(30,656||)||(17,763||)|
|Other (expense) income:|
|Loss on early extinguishment of debt||-||(1,062||)||(3,398||)||(1,062||)|
|Royalty interest obligation||(161||)||(143||)||(247||)||(425||)|
|Total other expense, net||(2,021||)||(1,670||)||(6,955||)||(2,427||)|
|Loss before income taxes||(14,031||)||(8,296||)||(37,611||)||(20,190||)|
|Income tax benefit||-||-||442||-|
|Net loss per share:|
|Basic and diluted net loss per common share||$||(0.42||)||$||(0.27||)||$||(1.13||)||$||(0.72||)|
|Weighted average common shares outstanding:|
|Basic and diluted||33,083,289||30,953,635||32,896,294||28,160,471|
|Pacira Pharmaceuticals, Inc.|
|Condensed Consolidated Balance Sheets|
|June 30,||December 31,|
|Cash and cash equivalents, restricted cash and short-term investments||$||96,954||$||42,573|
|Accounts receivable, net||7,756||4,352|
|Prepaid expenses and other current assets||2,559||1,920|
|Total current assets||121,490||60,922|
|Fixed assets, net||42,065||39,116|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Current portion of royalty interest obligation||891||823|
|Current portion of deferred revenue||972||972|
|Total current liabilities||15,835||14,156|
|Long-term debt, net of discount||96,892||25,191|
|Royalty interest obligation||584||857|
|Total stockholders' equity||59,142||65,855|
|Total liabilities and stockholders' equity||$||178,430||$||112,054|
Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574
Pure Communications, Inc.
Susan Heins, 864-286-9597